ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

fexuprazan

Also written as “DWP14012”, “DWP14012 20mg” and “DWP14012 40mg”.

Its studies are mostly in Esophagitis · Gastroesophageal Reflux · Stomach Ulcer · Peptic Ulcer · Non-Erosive Reflux Disease, led by 2 companies.

Drug pageFexuprazan: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 8, 202629 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewoong Pharmaceuticalits history only285 open or runningphase 4since Apr 8, 2026Mar 16, 2016Dec 2027phase 4 · NCT07533266
GlaxoSmithKline10 open or runningphase 1since Dec 15, 2011Dec 15, 2011none ahead

Also a collaborator on its studies: Shanghai Haini Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2011First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT01495026 · 63 enrolled · Australia

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448

Studies

The one study GlaxoSmithKline leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01495026Prostatic Hyperplasia · Australia1CompletedApr 3, 201263

How it is read

Names in the registry

  • “DWP14012”, 10 entries
  • “DWP14012 20mg”, 3 entries
  • “DWP14012 40mg”, 3 entries
  • “DWP14012 tablet A”, 3 entries
  • “DWP14012 tablet B”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.